Targeted Oncology reviews trending news online for the week of October 16, 2020, including updates in oncology.
This week, the FDA granted approval to pembrolizumab (Keytruda) as treatment of patients with relapsed/refractory classical Hodgkin lymphoma. The FDA accepted an investigational New Drug Application (NDA) for an investigational CDK2/4/6 inhibitor for high-grade gliomas. A rolling New Drug Application was initiated seeking approval of a treatment for patients with myelofibrosis with severe thrombocytopenia.
A novel small molecule received a Fast Track designation for the treatment of locally advanced or metastatic solid tumors. The FDA also granted an Orphan Drug designation to a novel monoclonal antibody in multiple gastrointestinal malignancies.
During a presentation at the National Comprehensive Cancer Institute 2020 Virtual Congress: Hematologic Malignancies, Shaji K. Kumar, MD, explained that each case of multiple myeloma requires a long-term strategy that starts with a strong approach in the frontline setting.
A number of targeted agents have been approved in the setting of metastatic breast cancer, which has allowed for more personalized treatment approaches and underscores the importance of genomic testing.
Lori J. Wirth, MD, of Massachusetts General Hospital, discussed the findings from an analysis of the patient-reported outcomes observed in the LIBRETTO-001 study of selpercatinib in patients with RET-driven thyroid cancers.
Tazemetostat (Tazverik) as a single agent demonstrated clinically meaningful durable responses as treatment of patients with heavily pretreated relapsed/refractory follicular lymphoma, according to findings from a phase 2 study.
The first CD19/22-directed dual targeting chimeric antigen receptor (CAR) T cell AUTO3 demonstrated a tolerable and best-in-class safety profile as treatment of patients with relapsed/refractory diffuse large B-cell lymphoma, according to findings from the phase 1 cohorts of the ALEXANDER study.
Natalie S. Callander, MD, of the University of Wisconsin, discusses the role of CAR T-cell therapy as treatment of patients with multiple myeloma.
Kenneth C. Anderson, MD, of Dana-Farber Cancer Institute, discusses how he has seen the treatment paradigm transform over the last decade in multiple myeloma.